-- Thymus cancers are uncommon cancers that start in the thymus. Symptoms include shortness of breath, cough, chest pain, trouble swallowing, loss of appetite, headaches and weight loss. Predisposing factor include age and other autoimmune diseases such as myasthenia gravis, pure red cell aplasia, or hypogammaglobulinemia.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/740551-thymic-carcinoma-pipeline-review-h2-2016
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Thymic Carcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thymic Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thymic Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thymic Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Thymic Carcinoma.
Thymic Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thymic Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Thymic Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thymic Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thymic Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thymic Carcinoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thymic Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thymic Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Thymic Carcinoma Overview 6
Therapeutics Development 7
Pipeline Products for Thymic Carcinoma - Overview 7
Pipeline Products for Thymic Carcinoma - Comparative Analysis 8
Thymic Carcinoma - Therapeutics under Development by Companies 9
Thymic Carcinoma - Therapeutics under Investigation by Universities/Institutes 10
Thymic Carcinoma - Pipeline Products Glance 11
Clinical Stage Products 11
Thymic Carcinoma - Products under Development by Companies 12
Thymic Carcinoma - Products under Investigation by Universities/Institutes 13
Thymic Carcinoma - Companies Involved in Therapeutics Development 14
Merck & Co., Inc. 14
Novartis AG 15
Onxeo SA 16
Sumitomo Dainippon Pharma Co., Ltd. 17
Taiwan Liposome Company, Ltd. 18
Tiziana Life Sciences Plc 19
Thymic Carcinoma - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
amrubicin hydrochloride - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
belinostat - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
milciclib - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
pasireotide ER - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
pembrolizumab - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Access Report @ https://www.wiseguyreports.com/reports/740551-thymic-carcinoma-pipeline-review-h2-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 146313
Google
RSS